Ratings OncoCyte Corporation

Equities

OCX

US68235C2061

Real-time Estimate Cboe BZX Other stock markets 14:43:16 06/05/2024 BST			5-day change	1st Jan Change
2.66 ^USD	0.00%		+7.26%	+6.40%

04-25	OncoCyte Corporation announced that it has received $15.807655 million in funding	CI
04-16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ONCOCYTE CORPORATION	+6.40%	35.55M	D+
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B	B+
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B	B+
ARGENX SE	+4.80%	22.94B	B
BIONTECH SE	-12.15%	22.34B	B+
GENMAB A/S	-6.59%	19.25B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.08B	A-
BEIGENE, LTD.	-10.04%	16.96B	B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B	C+
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders